- IQVIA is well-positioned to capitalise on market crosscurrents in its end-markets, with tech integration accelerated from the pandemic.
- Second quarter revenues came in well above consensus and illustrate the foundation IQV will work on for the remainder of FY2021.
- The company's book to bill ratio came in on healthy figures, even when stripping out passthroughs.
- We feel shares are worth $270 on a four-year normalised 33x FCF using a blend of FY2021 and FY2022 FCF estimates.
- Here we cover all of the moving parts in the investment debate for the benefit of investors' own reasoning.
For further details see:
IQVIA: Market Crosscurrents In Clinical And Adjacent Markets